Research & Development Programme 2

OCT130401 is a drug/device combination, which will look like an asthma inhaler.  Pre-clinical development for OCT130401 has been completed and it is ready to enter Phase I clinical trials. The initial target for OCT130401 is an orphan indication, Trigeminal Neuralgia.

Trigeminal Neuralgia 

Trigeminal Neuralgia (TN) is a severe type of face pain.  It causes debilitating and excruciating pain, has a fast and unexpected onset and because of this has been difficult to treat. People living with TN experience an intense, stabbing electric shock-like pain. Each episode may only last a few seconds or minutes, but some people will suffer multiple (up to 100) episodes in one day.[i]   Our medicine will be designated orphan status and delivered via an inhaler which may mean faster onset of pain relief when compared to other routes.[ii]. Cases are increasing with between approximately 10,000 and 15,000 new cases in the United States diagnosed each year.[iii] We estimate that in 2021 there were more than 77,000 people living with the condition in the UK.[iv]